Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419946 | 1.00 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL29072518 | 0.72 | — | — | |
| SCHEMBL6903182 | 0.69 | GSK3A (0.40) | GSK3AGSK3B | |
| SCHEMBL15760112 | 0.69 | GSK3A (0.36) | GSK3AGSK3B | |
| SCHEMBL15760108 | 0.69 | GSK3A (0.36) | GSK3AGSK3B | |
| SCHEMBL29362249 | 0.68 | — | — | |
| SCHEMBL5799303 | 0.68 | — | — | |
| SCHEMBL29535701 | 0.68 | — | — | |
| SCHEMBL2779620 | 0.68 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL8325743 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112321593-A | Preparation method of indolo [1,2-a ] quinazoline-6 (5H) -ketone compound | 浙江理工大学 | 2021-02-05 | — | — | CN | claimed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | claimed |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118076612-A | Sulfur-containing heteroaromatic tricyclic KRAS inhibitors | 医睿世康药业研发公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-220933309-U | Display panel | TCL华星光电技术有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4347603-A1 | SULFUR-CONTAINING HETEROAROMATIC TRICYCLIC KRAS INHIBITORS | Erasca, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-114807987-B | Electrochemical method for preparing fused polycyclic quinazolinone derivative | 哈尔滨工业大学（深圳） | 2023-10-03 | — | — | CN | disclosed |
| WO-2023183755-A1 | TRICYCLIC PYRIMIDONES | ERASCA, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-116615428-A | Tricyclic pyridones and pyrimidinones | 医睿世康药业研发公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116547280-A | Benzo [ h ] quinazolin-4-amine and thieno [3,2-h ] quinazolin-4-amine derivatives for the treatment of cancer | 雷多纳治疗公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-112321593-A | Preparation method of indolo [1,2-a ] quinazoline-6 (5H) -ketone compound | 浙江理工大学 | 2021-02-05 | — | — | CN | disclosed |
| WO-2020182779-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2020-09-17 | — | — | WO | disclosed |
| CN-102939296-B | Metal complex | MERCK PATENT GMBH (DE) | 2016-02-10 | — | — | CN | disclosed |
| CN-102939296-A | Metal complexes | MERCK PATENT GMBH | 2013-02-20 | — | — | CN | disclosed |
| EP-1846410-A2 | DIHYDROQUINAZOLINONES AS 5HT MODULATORS | Bristol-Myers Squibb Company (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006086464-A2 | DIHYDROQUINAZOLINONES AS 5HT MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| CN-1050355-C | Fused bicyclic pyrimidinones, fungicidal compositions containing them and their use | DU PONT (US) | 2000-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | DHFR, TYMS, TYMP | GSK3A 4223/4885GSK3B 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.